表紙
市場調查報告書

血液腫瘤檢驗的全球市場 - 至2024年的預測:急性骨髓性白血病,急性淋巴球性白血病,非何杰金氏淋巴瘤,何杰金氏淋巴瘤

Hemato Oncology Testing Market by Product & Services (Assay Kits, Services), Cancer (Leukemia (Acute Lymphoblastic, Acute Myeloid), Non-Hodgkin's Lymphoma), Technology (PCR, NGS, IHC), End-User - Global Forecast to 2024

出版商 MarketsandMarkets 商品編碼 876617
出版日期 內容資訊 英文 117 Pages
訂單完成後即時交付
價格
Back to Top
血液腫瘤檢驗的全球市場 - 至2024年的預測:急性骨髓性白血病,急性淋巴球性白血病,非何杰金氏淋巴瘤,何杰金氏淋巴瘤 Hemato Oncology Testing Market by Product & Services (Assay Kits, Services), Cancer (Leukemia (Acute Lymphoblastic, Acute Myeloid), Non-Hodgkin's Lymphoma), Technology (PCR, NGS, IHC), End-User - Global Forecast to 2024
出版日期: 2019年06月24日內容資訊: 英文 117 Pages
簡介

血液腫瘤檢驗市場預計將從2019年的20億美元,擴大到2024年的40億美元。市場在2019年∼2024年間,預測將以年複合成長率 (CAGR) 14.8%的速度成長。

本報告提供全球血液腫瘤檢驗市場相關調查分析,市場概要,產業趨勢,各市場區隔的市場分析,競爭情形,主要企業等相關的系統性資訊。

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 重要考察

  • 血液腫瘤檢驗:市場概要
  • 北美 - 血液腫瘤檢驗市場:各產品、服務
  • 血液腫瘤檢驗市場各地區概述

第5章 市場概要

  • 簡介
  • 市場動態
    • 促進因素
    • 阻礙因素
    • 機會
    • 課題

第6章 血液腫瘤檢驗的全球市場:各產品、服務

  • 簡介
  • 服務
  • 化驗套件

第7章 血液腫瘤檢驗的全球市場:癌症的各類型

  • 簡介
  • 白血病
    • 急性骨髓性白血病
    • 急性淋巴球性白血病
    • 其他
  • 淋巴瘤
    • 非何杰金氏淋巴瘤
    • 何杰金氏淋巴瘤
  • 其他癌症

第8章 血液腫瘤檢驗的全球市場:各技術

  • 簡介
  • PCR
  • IHC
  • NGS
  • 細胞遺傳學
  • 其他

第9章 血液腫瘤檢驗的全球市場:各終端用戶

  • 簡介
  • 臨床檢驗室
  • 醫院
  • 學術、研究機關
  • 其他

第10章 血液腫瘤檢驗的全球市場:各地區

  • 簡介
  • 北美
  • 歐洲
  • 亞太地區
  • 其他

第11章 競爭情形

  • 概要
  • 市場排行榜分析
  • 主要策略

第12章 企業簡介

  • F. HOFFMAN-LA ROCHE LTD.
  • ABBOTT LABORATORIES
  • QIAGEN N.V.
  • THERMO FISHER SCIENTIFIC, INC.
  • ILLUMINA, INC.
  • BIO-RAD LABORATORIES, INC.
  • MOLECULARMD (ICON PLC的子公司)
  • ARCHERDX, INC.
  • ARUP LABORATORIES INC.
  • ASURAGEN, INC.
  • INVIVOSCRIBE, INC.
  • ADAPTIVE BIOTECHNOLOGIES.

第13章 附錄

目錄
Product Code: MD 7180

"Hemato oncology testing market to register a CAGR of 14.8% from 2019 to 2024"

The hemato oncology testing market is projected to reach USD 4.0 billion by 2024 from USD 2.0 billion in 2019, at a CAGR of 14.8% during the forecast period. Growth in this market is mainly driven by the rising incidences & prevalence of leukemia, increasing collaborations for developing new assay kits, and the growing focus on personalized medicine.

"Services accounted for the larger share of the hemato oncology testing market in 2018"

Based on product & service, the market is segmented into assay kits and services. In 2018, the services segment accounted for a larger share of this market majorly due to the high prevalence of leukemia & lymphoma. The market is set to grow on account of increasing collaborations between hemato oncology testing product manufacturers and pharmaceutical companies.

"Leukemia accounted for the largest share of the hemato oncology testing market in 2018"

Based on cancer type, the hemato oncology testing market has been segmented into three types- leukemia, lymphoma, and other cancers. Leukemia accounted for the largest share in 2018 and is anticipated to witness the highest growth rate during the forecast period due to the need for continuous monitoring of leukemia patients. In addition, increasing awareness about checking the status of minimal residual disease (MRD) in leukemia patients is another factor supporting market growth.

"North America dominates the hemato oncology testing market"

North America, which includes the US and Canada, accounted for the largest share of the hemato oncology testing in 2018. The large share of this market segment can be attributed to the availability of reimbursement for hemato oncology testing products, increasing awareness regarding advanced treatment theories, and the strong presence of industry players in the region.

Breakdown of supply-side primary interviews, by company type, designation, and region:

  • By Company Type: Tier 1: 70% , Tier 2: 20%, and Tier 3: 10%
  • By Designation: C-level: 30%, Director-level: 20%, and Others: 50%
  • By Region: North America: 35%, Europe: 24%, Asia: 25%, and the RoW: 16%

The major players operating in this market are: F. Hoffmann-La Roche Ltd. (Switzerland), Abbott Laboratories (US), Thermo Fisher Scientific, Inc. (US), QIAGEN N.V. (Germany), Bio-Rad Laboratories, Inc. (US), Illumina, Inc. (US), MolecularMD (Ireland), Invivoscribe, Inc. (US), Asuragen, Inc. (US), Adaptive Biotechnologies (US), ArcherDx, Inc. (US), and ARUP Laboratories Inc. (US).

Research Coverage:

This report studies the hemato oncology testing market based on product & service, cancer type, technology, end user, and region. The report also analyzes factors (such as drivers, restraints, challenges, and opportunities) affecting market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micro-markets with respect to their growth trends, prospects, and contributions to the total hemato oncology testing market. The report forecasts the revenue of the market segments with respect to four major regions.

Reasons to Buy the Report:

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on the hemato oncology testing offered by the top 12 players in the market. The report analyzes the hemato oncology testing market by product and region
  • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various hemato oncology testing across key geographic regions
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the hemato oncology testing market
  • Competitive Assessment: In-depth assessment of market shares and strategies of the leading players in the hemato oncology testing market

Table of Contents

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
    • 1.2.1. MARKETS COVERED
    • 1.2.2. YEARS CONSIDERED FOR THE STUDY
  • 1.3. CURRENCY
  • 1.4. LIMITATIONS
  • 1.5. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. SECONDARY DATA
    • 2.1.1. KEY DATA FROM SECONDARY SOURCES
  • 2.2. PRIMARY DATA
    • 2.2.1. KEY DATA FROM PRIMARY SOURCES
  • 2.3. MARKET SIZE ESTIMATION
    • 2.3.1. BOTTOM-UP APPROACH
    • 2.3.2. TOP-DOWN APPROACH
  • 2.4. MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.5. ASSUMPTIONS FOR THE STUDY

3. EXECUTIVE SUMMARY

4. PREMIUM INSIGHTS

  • 4.1. HEMATO-ONCOLOGY TESTING: MARKET OVERVIEW
  • 4.2. NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT AND SERVICE (2018)
  • 4.3. GEOGRAPHICAL SNAPSHOT OF THE HEMATO-ONCOLOGY TESTING MARKET

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. MARKET DYNAMICS
    • 5.2.1. DRIVERS
      • 5.2.1.1. Increasing incidence of hematologic cancer
      • 5.2.1.2. Increasing collaborations
      • 5.2.1.3. Increasing conferences on personalized medicine
    • 5.2.2. OPPORTUNITIES
      • 5.2.2.1. Drug diagnostics co-development
      • 5.2.2.2. Emerging markets
    • 5.2.3. RESTRAINTS
      • 5.2.3.1. Uncertain reimbursement scenario in different regions
      • 5.2.3.2. Complex regulatory frameworks delaying the approval of new molecular diagnostic tests
    • 5.2.4. CHALLENGES
      • 5.2.4.1. Intellectual property rights protection issues

6. HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE

  • 6.1. INTRODUCTION
  • 6.2. SERVICES
    • 6.2.1. RISING INCIDENCE OF HEMATOLOGIC CANCER TO INCREASE THE DEMAND FOR HEMATO-ONCOLOGY SERVICES
  • 6.3. ASSAY KITS
    • 6.3.1. GROWING FOCUS ON THE DEVELOPMENT OF ADVANCED ASSAY KITS TO DRIVE THE GROWTH OF THIS MARKET SEGMENT

7. HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE

  • 7.1. INTRODUCTION
  • 7.2. LEUKEMIA
    • 7.2.1. ACUTE MYELOID LEUKEMIA
      • 7.2.1.1. AML IS THE MOST COMMON ACUTE LEUKEMIA AFFECTING ADULTS
    • 7.2.2. ACUTE LYMPHOCYTIC LEUKEMIA
      • 7.2.2.1. North America accounted for the largest share of the ALL segment
    • 7.2.3. OTHER LEUKEMIAS
  • 7.3. LYMPHOMA
    • 7.3.1. NON-HODGKIN LYMPHOMA
      • 7.3.1.1. Non-Hodgkin lymphoma holds the largest share of the market for lymphoma
    • 7.3.2. HODGKIN LYMPHOMA
      • 7.3.2.1. APAC hemato-oncology testing market for Hodgkin lymphoma will grow at the highest rate
  • 7.4. OTHER CANCERS

8. HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY

  • 8.1. INTRODUCTION
  • 8.2. PCR
    • 8.2.1. PCR ACCOUNTED FOR THE LARGEST SHARE OF THE HEMATO-ONCOLOGY TESTING MARKET IN 2018
  • 8.3. IHC
    • 8.3.1. IHC ACCOUNTED FOR THE SECOND-LARGEST SHARE OF THE HEMATO-ONCOLOGY TESTING MARKET
  • 8.4. NGS
    • 8.4.1. NGS IS EXPECTED TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD
  • 8.5. CYTOGENETICS
    • 8.5.1. NORTH AMERICA ACCOUNTED FOR THE LARGEST SHARE OF THE CYTOGENETICS MARKET
  • 8.6. OTHER TECHNOLOGIES

9. HEMATO-ONCOLOGY TESTING MARKET, BY END USER

  • 9.1. INTRODUCTION
  • 9.2. CLINICAL LABORATORIES
    • 9.2.1. PRESENCE OF ROBUST INFRASTRUCTURE IS THE MAJOR DRIVING FACTOR FOR THIS SEGMENT
  • 9.3. HOSPITALS
    • 9.3.1. HOSPITALS ACCOUNTED FOR THE SECOND-LARGEST SHARE OF THE MARKET, BY END USER
  • 9.4. ACADEMIC & RESEARCH INSTITUTES
    • 9.4.1. APAC MARKET FOR ACADEMIC & RESEARCH INSTITUTES WILL GROW AT THE HIGHEST RATE
  • 9.5. OTHER END USERS

10. HEMATO-ONCOLOGY TESTING MARKET, BY REGION

  • 10.1. INTRODUCTION
  • 10.2. NORTH AMERICA
    • 10.2.1. US
      • 10.2.1.1. The US dominates the North American hemato-oncology testing market
    • 10.2.2. CANADA
      • 10.2.2.1. Initiatives undertaken by healthcare authorities in the country to ensure the delivery of better public healthcare to support the growth of the hemato-oncology testing market in Canada
  • 10.3. EUROPE
    • 10.3.1. RISING FOCUS ON BIOMARKER DEVELOPMENT IN EU COUNTRIES TO SUPPORT MARKET GROWTH
  • 10.4. ASIA PACIFIC
    • 10.4.1. ASIA PACIFIC MARKET TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD
  • 10.5. REST OF THE WORLD

11. COMPETITIVE LANDSCAPE

  • 11.1. OVERVIEW
  • 11.2. MARKET RANKING ANALYSIS, 2017
  • 11.3. KEY STRATEGIES
    • 11.3.1. PRODUCT LAUNCHES & APPROVALS, 2016-2019
    • 11.3.2. EXPANSIONS, 2016-2019
    • 11.3.3. PARTNERSHIPS AND COLLABORATIONS, 2016-2019
    • 11.3.4. ACQUISITIONS, 2016-2019

12. COMPANY PROFILES (Business Overview, Products Offered, Recent Developments, MnM View)*

  • 12.1. F. HOFFMAN-LA ROCHE LTD.
  • 12.2. ABBOTT LABORATORIES
  • 12.3. QIAGEN N.V.
  • 12.4. THERMO FISHER SCIENTIFIC, INC.
  • 12.5. ILLUMINA, INC.
  • 12.6. BIO-RAD LABORATORIES, INC.
  • 12.7. MOLECULARMD (SUBSIDIARY OF ICON PLC)
  • 12.8. ARCHERDX, INC.
  • 12.9. ARUP LABORATORIES INC.
  • 12.10. ASURAGEN, INC.
  • 12.11. INVIVOSCRIBE, INC.
  • 12.12. ADAPTIVE BIOTECHNOLOGIES.

*Details on Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.

13. APPENDIX

  • 13.1. INSIGHTS OF INDUSTRY EXPERTS
  • 13.2. DISCUSSION GUIDE
  • 13.3. KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.4. AVAILABLE CUSTOMIZATIONS
  • 13.5. RELATED REPORTS
  • 13.6. AUTHOR DETAILS

LIST OF TABLES

  • TABLE 1: HEMATOLOGIC CANCER INCIDENCE, BY TYPE, 2018-2040
  • TABLE 2: GERIATRIC POPULATION, BY REGION, 2015 VS. 2030
  • TABLE 3: HEALTH EXPENDITURE PER CAPITA, BY COUNTRY, 2009 VS. 2016
  • TABLE 4: INCIDENCE OF HEMATOLOGIC CANCERS, BY COUNTRY, 2018 VS. 2030
  • TABLE 5: REIMBURSEMENT SCENARIO FOR HEMATO-ONCOLOGY TESTING PRODUCTS ACROSS REGIONS
  • TABLE 6: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2017-2024 (USD MILLION)
  • TABLE 7: HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 8: HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 9: HEMATO-ONCOLOGY TESTING ASSAY KITS MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 10: HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE, 2017-2024 (USD MILLION)
  • TABLE 11: HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 12: HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 13: HEMATO-ONCOLOGY TESTING MARKET FOR ACUTE MYELOID LEUKEMIA, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 14: HEMATO-ONCOLOGY TESTING MARKET FOR ACUTE LYMPHOCYTIC LEUKEMIA, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 15: HEMATO-ONCOLOGY TESTING MARKET FOR OTHER LEUKEMIAS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 16: HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 17: HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 18: HEMATO-ONCOLOGY TESTING MARKET FOR NON-HODGKIN LYMPHOMA, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 19: HEMATO-ONCOLOGY TESTING MARKET FOR HODGKIN LYMPHOMA, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 20: HEMATO-ONCOLOGY TESTING MARKET FOR OTHER CANCERS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 21: HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 22: HEMATO-ONCOLOGY TESTING MARKET FOR PCR, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 23: HEMATO-ONCOLOGY TESTING MARKET FOR IHC, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 24: HEMATO-ONCOLOGY TESTING MARKET FOR NGS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 25: HEMATO-ONCOLOGY TESTING MARKET FOR CYTOGENETICS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 26: HEMATO-ONCOLOGY TESTING MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 27: HEMATO-ONCOLOGY TESTING MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 28: HEMATO-ONCOLOGY TESTING MARKET FOR REFERENCE LABORATORIES, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 29: HEMATO-ONCOLOGY TESTING MARKET FOR HOSPITALS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 30: HEMATO-ONCOLOGY TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 31: HEMATO-ONCOLOGY TESTING MARKET FOR OTHER END USERS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 32: HEMATO-ONCOLOGY TESTING MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 33: NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 34: NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2017-2024 (USD MILLION)
  • TABLE 35: NORTH AMERICA: HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 36: NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE, 2017-2024 (USD MILLION)
  • TABLE 37: NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 38: NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 39: NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 40: NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 41: US: LEUKEMIA AT A GLANCE
  • TABLE 42: US: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2017-2024 (USD MILLION)
  • TABLE 43: US: HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE, 2017-2024 (USD MILLION)
  • TABLE 44: US: HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 45: US: HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 46: US: HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 47: US: HEMATO-ONCOLOGY TESTING MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 48: CANADA: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2017-2024 (USD MILLION)
  • TABLE 49: CANADA: HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE, 2017-2024 (USD MILLION)
  • TABLE 50: CANADA: HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 51: CANADA: HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 52: CANADA: HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 53: CANADA: HEMATO-ONCOLOGY TESTING MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 54: INCIDENCE OF LEUKEMIA, BY COUNTRY, 2018-2035
  • TABLE 55: EUROPE: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2017-2024 (USD MILLION)
  • TABLE 56: EUROPE: HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 57: EUROPE: HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE, 2017-2024 (USD MILLION)
  • TABLE 58: EUROPE: HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 59: EUROPE: HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 60: EUROPE: HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 61: EUROPE: HEMATO-ONCOLOGY TESTING MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 62: GERIATRIC POPULATION, BY COUNTRY, 2015 VS. 2030
  • TABLE 63: ASIA PACIFIC: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2017-2024 (USD MILLION)
  • TABLE 64: ASIA PACIFIC: HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 65: ASIA PACIFIC: HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE, 2017-2024 (USD MILLION)
  • TABLE 66: ASIA PACIFIC: HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 67: ASIA PACIFIC: HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 68: ASIA PACIFIC: HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 69: ASIA PACIFIC: HEMATO-ONCOLOGY TESTING MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 70: ROW: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2017-2024 (USD MILLION)
  • TABLE 71: ROW: HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 72: ROW: HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE, 2017-2024 (USD MILLION)
  • TABLE 73: ROW: HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 74: ROW: HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 75: ROW: HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 76: ROW: HEMATO-ONCOLOGY TESTING MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 77: RANKING OF COMPANIES IN THE HEMATO-ONCOLOGY TESTING MARKET, 2018

LIST OF FIGURES

  • FIGURE 1: HEMATO-ONCOLOGY TESTING MARKET
  • FIGURE 2: RESEARCH DESIGN
  • FIGURE 3: BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 4: HEMATO-ONCOLOGY TESTING MARKET: BOTTOM-UP APPROACH
  • FIGURE 5: HEMATO-ONCOLOGY TESTING MARKET: TOP-DOWN APPROACH
  • FIGURE 6: DATA TRIANGULATION METHODOLOGY
  • FIGURE 7: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT AND SERVICE, 2019 VS. 2024 (USD MILLION)
  • FIGURE 8: HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE, 2019 VS. 2024 (USD MILLION)
  • FIGURE 9: HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY, 2019 VS. 2024 (USD MILLION)
  • FIGURE 10: HEMATO-ONCOLOGY TESTING MARKET, BY END USER, 2019 VS. 2024 (USD MILLION)
  • FIGURE 11: HEMATO-ONCOLOGY TESTING MARKET, BY REGION, 2019 VS. 2024 (USD MILLION)
  • FIGURE 12: INCREASING INCIDENCE OF HEMATOLOGY CANCER TO DRIVE MARKET GROWTH
  • FIGURE 13: SERVICES TO DOMINATE THE NORTH AMERICAN MARKET IN 2018
  • FIGURE 14: NORTH AMERICA ACCOUNTED FOR THE LARGEST MARKET SHARE IN 2018
  • FIGURE 15: HEMATO-ONCOLOGY TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, & CHALLENGES
  • FIGURE 16: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE (2019 VS. 2024)
  • FIGURE 17: HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE (2019 VS. 2024)
  • FIGURE 18: HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY (2019 VS. 2024)
  • FIGURE 19: HEMATO-ONCOLOGY TESTING MARKET, BY END USER (2019 VS. 2024)
  • FIGURE 20: HEMATO-ONCOLOGY TESTING MARKET, BY REGION (2019 VS. 2024)
  • FIGURE 21: NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET SNAPSHOT
  • FIGURE 22: KEY DEVELOPMENTS IN THE HEMATO-ONCOLOGY TESTING MARKET FROM 2016 TO 2018
  • FIGURE 23: ROCHE DIAGNOSTIC: COMPANY SNAPSHOT (2018)
  • FIGURE 24: ABBOTT LABORATORIES: COMPANY SNAPSHOT (2018)
  • FIGURE 25: QIAGEN N.V.: COMPANY SNAPSHOT (2018)
  • FIGURE 26: THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2018)
  • FIGURE 27: ILLUMINA, INC.: COMPANY SNAPSHOT (2018)
  • FIGURE 28: BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2018)
  • FIGURE 29: ICON PLC: COMPANY SNAPSHOT (2018)
Back to Top